Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2022 08:30 ET | Source: Panbela Therapeutics, Inc.

Panbela Schedules Conference Call on March 24, 2022, to Report 2021 Fourth Quarter Financial Results

MINNEAPOLIS, March 08, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
March 07, 2022 08:30 ET | Source: Panbela Therapeutics, Inc.

Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)

MINNEAPOLIS, March 07, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
February 22, 2022 08:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.

Creates late-stage, diversified pipeline that uses a multi-targeted approach to reset dysregulated biology to address considerable unmet needsCombined pipeline extends from pre-clinical to...
January 26, 2022 09:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Initiates a Randomized, Double-Blind, Placebo-Controlled Study (ASPIRE) of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

MINNEAPOLIS, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
January 24, 2022 09:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2022 ASCO GI Meeting

Interim data presented in poster reflects median overall survival of 12.0 months, not yet final, and an objective response rate of 48%, both greater than historical rates reported for standard of care...
December 14, 2021 09:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces Positive Preclinical Data Strongly Supporting the Activity of SBP-101 in Ovarian Cancer Cell Lines; Development Program for SBP-101’s Expansion into Ovarian Cancer Expected in 1H 2022

MINNEAPOLIS, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today...
November 18, 2021 09:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Gastrointestinal Cancers Symposium

MINNEAPOLIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
November 10, 2021 16:15 ET | Source: Panbela Therapeutics, Inc.

Panbela Provides Business Update and Reports Q3 2021 Financial Results

MINNEAPOLIS, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
October 25, 2021 09:00 ET | Source: Panbela Therapeutics, Inc.

Panbela Schedules Conference Call on November 10, 2021, to Report 2021 Third Quarter Financial Results

MINNEAPOLIS , Oct. 25, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of...
September 07, 2021 09:00 ET | Source: Panbela Therapeutics, Inc.

Panbela to Present at Upcoming Investor Conferences

MINNEAPOLIS, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of...